Skip to content

A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

Hidradenitis Suppurativa

This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 to 75

Participation Criteria

Inclusion Criteria:

* Have a diagnosis of HS for at least 12 months.
* Have HS lesions in at least 2 distinct anatomical regions. At least 1 of the lesions must be at least Hurley Stage II or III.
* Have an (abscess plus inflammatory nodule) count of at least 5.
* Agree to use topical antiseptics daily.
* Had an inadequate response or intolerance to a 28-day course of oral antibiotics.

Exclusion Criteria:

* Have more than 20 draining fistulae.
* Have had surgical treatment for HS in the last 4 weeks before randomization.
* Have an active skin disease or condition, that could interfere with the assessment of HS.
* Have a current or recent acute, active infection.
* Are immunocompromised.
* Have a history of chronic alcohol abuse, IV drug abuse, or other illicit drug abuse within 1 year before screening.

Study Location

Alberta Dermasurgery Centre
Alberta Dermasurgery Centre
Edmonton, Alberta
Canada

Contact Study Team

DermEffects - Probity - PPDS
DermEffects - Probity - PPDS
London, Ontario
Canada

Contact Study Team

Beacon Dermatology
Beacon Dermatology
Calgary, Alberta
Canada

Contact Study Team

Simcoderm Medical & Surgical Dermatology Centre
Simcoderm Medical & Surgical Dermatology Centre
Barrie, Ontario
Canada

Contact Study Team

Wiseman Dermatology Research Inc.
Wiseman Dermatology Research Inc.
Winnipeg, Manitoba
Canada

Contact Study Team

Center de Recherche St Louis
Center de Recherche St Louis
Quebec City, Quebec
Canada

Contact Study Team

Brunswick Dermatology Center
Brunswick Dermatology Center
Fredericton, New Brunswick
Canada

Contact Study Team

Study Sponsored By
Eli Lilly and Company
Participants Required
More Information
Study ID: NCT06046729